Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OMEPRAZOLE AND SODIUM BICARBONATE vs ACETAMINOPHEN AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Duodenal ulcer,Gastric ulcer,Gastroesophageal reflux disease (GERD),Erosive esophagitis,Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Helicobacter pylori eradication (in combination with antibiotics),Prevention of upper gastrointestinal bleeding in critically ill patients (off-label),Treatment of dyspepsia (off-label)
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
Terminal elimination half-life of omeprazole is approximately 0.5-1 hour. However, the pharmacodynamic effect (gastric acid suppression) lasts longer due to accumulation in parietal cells. Half-life does not correlate with duration of acid suppression.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Omeprazole is extensively metabolized in the liver by cytochrome P450 (CYP) enzymes, primarily CYP2C19 and CYP3A4, to inactive metabolites. Sodium bicarbonate is not metabolized; it dissociates into sodium and bicarbonate ions.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Omeprazole is primarily metabolized by CYP2C19 and CYP3A4; metabolites are excreted renally (~77% as metabolites) and fecally (~20% as metabolites). Urinary excretion of unchanged omeprazole is negligible (<1%). Sodium bicarbonate is excreted renally as bicarbonate and carbon dioxide.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Omeprazole is 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
Apparent volume of distribution is approximately 0.3-0.5 L/kg, suggesting distribution into total body water. The active form accumulates in parietal cell canaliculi.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Oral bioavailability is approximately 30-40% after a single dose, increasing to 60-70% with repeated administration due to decreased first-pass metabolism. Bioavailability is not affected by food but is enhanced by the sodium bicarbonate component, which protects omeprazole from acid degradation.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
No dosage adjustment required for mild to moderate renal impairment; for severe renal impairment (GFR <30 m L/min), use with caution and monitor for sodium overload.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
For mild hepatic impairment (Child-Pugh class A), no adjustment; for moderate to severe impairment (Child-Pugh class B or C), maximum dose is 20 mg omeprazole once daily due to reduced metabolism.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Not established for omeprazole/sodium bicarbonate combination; for omeprazole alone, weight-based dosing: 10-15 mg once daily for weight 10-20 kg, 20 mg once daily for weight >20 kg.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
No specific dose adjustment; use lowest effective dose, monitor for electrolyte imbalance (sodium) and increased risk of Clostridium difficile infection.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
No FDA black box warning.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Gastric malignancy: Short-term treatment does not preclude presence of gastric malignancy.,Clostridioides difficile infection: May increase risk.,Bone fracture: Long-term use may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.,Hypomagnesemia: May cause low serum magnesium with prolonged use.,Cyanocobalamin (Vitamin B12) deficiency: Prolonged acid suppression may impair absorption.,Acute interstitial nephritis: Has been observed.,Cutaneous lupus erythematosus: May increase risk.,Interaction with methotrexate: May increase methotrexate toxicity.,Sodium content: Contains sodium bicarbonate; caution in patients on sodium-restricted diet.,Metabolic alkalosis: High doses of bicarbonate may cause metabolic alkalosis.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Hypersensitivity to omeprazole or sodium bicarbonate,Hypersensitivity to other proton pump inhibitors,Concurrent use of rilpivirine,Severe hypokalemia or metabolic alkalosis (due to bicarbonate component)
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Avoid taking with food or within 30 minutes of eating. High-fat meals may delay absorption. No specific food restrictions, but alcohol and spicy foods may exacerbate symptoms.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omeprazole is FDA Pregnancy Category C; sodium bicarbonate is not associated with teratogenicity.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Omeprazole is excreted into breast milk with an M/P ratio of approximately 0.1-0.2. Sodium bicarbonate is also excreted. At therapeutic doses, amounts are unlikely to affect the infant. Manufacturer advises caution, but use is generally considered compatible with breastfeeding.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
Pregnancy does not significantly alter omeprazole pharmacokinetics. No dose adjustment required, but use lowest effective dose due to limited safety data. Sodium bicarbonate dose may need adjustment if renal impairment or preeclampsia is present.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
Administer on an empty stomach 1 hour before a meal for maximal acid suppression. The sodium bicarbonate component provides rapid antacid effect and may cause belching or gastric distension. Avoid in patients with Bartter's syndrome, hypokalemia, or metabolic alkalosis. Monitor magnesium levels with prolonged use; hypomagnesemia can occur with PPIs. For patients unable to swallow capsules, the contents can be mixed with applesauce.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Take this medication 1 hour before a meal, usually once daily.,Swallow the capsule whole; do not crush or chew. If you have trouble swallowing, open the capsule and mix the granules with a tablespoon of applesauce, then swallow immediately.,Do not take with other antacids unless directed by your doctor.,Inform your doctor if you experience severe diarrhea, muscle cramps, irregular heartbeat, or signs of low magnesium (seizures, dizziness, abnormal heart rhythm).,Long-term use may increase risk of bone fractures, vitamin B12 deficiency, and kidney problems.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OMEPRAZOLE AND SODIUM BICARBONATE vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.
OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Sodium bicarbonate is an antacid that neutralizes gastric acid.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OMEPRAZOLE AND SODIUM BICARBONATE and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OMEPRAZOLE AND SODIUM BICARBONATE is: Omeprazole 20 mg plus sodium bicarbonate 1100 mg orally once daily before a meal; for gastroesophageal reflux disease, dose may be increased to 40 mg orally once daily for 4-8 weeks.. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining OMEPRAZOLE AND SODIUM BICARBONATE and ACETAMINOPHEN AND IBUPROFEN. The metabolism of Omeprazole can be decreased when combined with Ibuprofen. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No increased risk of major congenital malformations based on large cohort studies. Second and third trimesters: Limited data, but no evidence of fetal harm. Omepra. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.